MGC Pharmaceuticals in West Perth, Western Australia | Pharmaceutical company

MGC Pharmaceuticals

Locality: West Perth, Western Australia

Phone: +61 8 6382 3390

Address: 1202 Hay Street 6005 West Perth, WA, Australia

Website: http://mgcpharma.com.au

Likes: 2622

Add/Update information

Reviews

Tags

• Medical and health
• Pharmacy/chemists
• Medical supply store
• Pharmaceutical company

24.01.2022 Speaking on the results, MGCs Co-founder and Managing Director, Roby Zomer commented: "We are very pleased to have achieved these results, which have been completed in line with FDA requirements for COVID-19 studies and provide important data points for our Phase IIb and III trial design and protocols." https://thegreenfund.com/mgc-pharmas-share-prices-climb-fol

24.01.2022 https://stockhead.com.au//mgc-pharma-submits-patent-for-c/

24.01.2022 The Queensland branch of the Australian Medical Association and Australian Health Authorities have relaxed rules to make access to medicinal cannabis easier for patients. The new rules stipulate that any GP can prescribe medicinal cannabis to patients if they believe it is clinically appropriate and have obtained the required Commonwealth approval. Previously, only a handful of specialist doctors were able to prescribe medicinal cannabis, which had to be done via the national... TGA for each prescription to be issued. This means that a previous 10-week process has been reduced to just a few hours, a win for patients. This is a huge step forward for Australia, the health sector and for patients More information on this can be found here: https://www.9news.com.au//1f3941ec-787e-47d4-ba63-f91e04c1

23.01.2022 MGC Pharma is pleased to announce the successful submission of a patent application for CimetrATM to the Slovenian Intellectual Property Office (SIPO) #intellectualproperty #patent #pharma #healthcare #innovation #research https://londonstockexchange.com//cimetra-patent-s/14979020

23.01.2022 We are happy to support the research on the effect of Cannabis sativa L. root, leaf and inflorescence ethanol extracts on the chemotrophic response of entomopathogenic nematodes. The Results: Overall, EPNs were most attracted or repelled by inflorescence extracts, followed by leaves and roots. The most abundant terpene in hemp inflorescences was trans caryophyllene (38.2% on average), the highest contents of total cannabidiol, total cannabigerol and total tetrahydrocannabinol... were 9.65%, 0.89% and 0.62%, respectively. Conclusions: The attraction effect of S. sativa L. EE is a highly interesting outcome and could lead to the development of attractant compounds in EPN biological control. Cannabinoids and terpenes may be responsible for pronounced effects on EPN chemotaxis. #mgcpharma #MGCbotanic #MGCgenetics https://link.springer.com/artic/10.1007/s11104-020-04693-z

22.01.2022 MGC Pharmaceuticals outlines investment highlights at Proactive medicinal cannabis webinar The company is developing medicines that leverage its proprietary medicinal cannabis formula through clinical trials in Israel and Australia, enabling future medical product sales across the globe. Our Co-founder and MD Roby Zamer said the company was developing medicines that leveraged its proprietary medicinal cannabis formula through clinical trials in Israel and Australia, enabling ...future medical product sales across the globe following regulatory approvals. https://www.proactiveinvestors.com.au//mgc-pharmaceuticals

22.01.2022 MGC Pharma is pleased to have secured funding for three PhD students from the EU’s REDI for MGC’s medicinal cannabis research programmes as part of its joint CannaHub initiative. CannaHub is a joint international medical research centre for medicinal cannabis innovation and technologies between MGC, the Royal Melbourne Institute of Technology (RMIT), which has a European hub in Barcelona, and The Hebrew University of Jerusalem (HUJI). The funds, which are spread over three ye...ars and tied to Cannahub, will help raise academic engagement with cannabinoids and the sector more widely. Read more about CannaHub and its research plans in BusinessCann https://businesscann.com/mgc-pharma-secures-e450000-eu-cas/

22.01.2022 A vote by the UN to reschedule cannabis and its derivatives to a schedule I drug (from schedule 4), is set to have a substantial positive impact on MXC and its growth https://prohibitionpartners.com//the-un-votes-to-recognis/ Read more about it here: https://stocknessmonster.com/announcemen/mxc.asx-6A1010765/

21.01.2022 MGC Pharma will be hosting a General Meeting on Thursday 2 July 2:30pm AWST via a webinar. To register for the webinar, please follow this link: https://us02web.zoom.us//register/WN_yl71BNGtTyKEUWgweV4QWQ

21.01.2022 More on CannaGlobal update for its Shareholders: The Godfather Of Canadian Cannabis Is launching A Psilocybin Startup https://www.forbes.com//the-godfather-of-canadian-cannab/

20.01.2022 A great feature in Stockhead's Weed Week which wraps up the week's global cannabis news https://stockhead.com.au//weed-week-lame-duck-us-congress/

20.01.2022 MGC Pharmaceuticals is sponsoring the Brazilian Medical Cannabis Summit taking place from the 9th 13th November. Our very own Dr Jonathan Grunfeld will be presenting and talking through our clinical trials on the effect of CBD and THC on various disorders. You can register to participate in the conference on the website: https://medicalcannabissummit.com.br/ Brazil is a strategically important region for MGC and recently we completed the first shipments of Mercury Pharma p...roducts which included the high THC ratio products directly to patients in Brazil. Brazil has a population of over 210m people and the National Healthcare Expenditure is estimated at A$267b with total pharmaceuticals expenditure estimated at A$24 billion per annum. According to Interfarma (Pharmaceutical Research Industry Association), the Brazilian pharmaceutical market is expected to grow from A$59.9 billion in 2019 to A$66 billion by 2023, through the selling of approximately 238 million units. #cannabis #brazil #healthcare #pharmaceutical

20.01.2022 While the COVID-19 pandemic has been incredibly challenging for the company, Zomer said it had also been an opportunity to learn more about themselves as a business and perhaps more importantly, how the business dealt with adversity. https://www.proactiveinvestors.com.au//mgc-pharmaceuticals

20.01.2022 Clinical Trials as a Vehicle to Cannabinoid Based Pharmaceutical Products for Medical Markets in the EU - Roby Zomer, Australia @ The International Congress on Clinical Trials in Cannabis (CT-Cann2019) https://www.ct-cann.com//Roby%20Zomer%20-%20CT%20as%20a%20

18.01.2022 https://stockhead.com.au//mgc-pharma-expands-footprint-wi/

18.01.2022 MGC Pharma is delighted to announce it has received a cannabis cultivation research permit from the Australian Office of Drug Control. Receipt of this permit allows MXC to proceed with botanical research projects in collaboration with RMIT University which includes cultivating and breeding strains in order to test against cancer cells. The research will leverage existing MGC Pharma IP and focus on identifying new cannabinoids and formulas, initially targeting melanoma and p...rostate cancer. More information can be found here: https://www.asx.com.au/asxp/20200714/pdf/44khmrfm863sgs.pdf

17.01.2022 MGC Pharma has received a new A$1m order for #ArtemiC Rescue production from global distributor Swiss PharmaCan AG. ArtemiC is a nutraceutical supplement for the alleviation of #Covid19 symptoms #biopharma #biotechnology #pharmaceuticals https://www.londonstockexchange.com//new-artemic-/14961100

17.01.2022 MGC Pharma is delighted to announce the interim results of ArtemiC Phase II clinical trial on COVID-19 infected patients meets all Primary Objectives. The interim results data also strongly indicates a beneficial effect of ArtemiC on the related pain associated with COVID-19, with none of the actively treated participants reporting pain on the 15th day concluding the active monitoring phase, as opposed to those treated with placebo who continued to experience some level of pain. Read the announcement here: https://www.asx.com.au/asxp/20200820/pdf/44lq4tqmnpmgyb.pdf

17.01.2022 MGC Pharma is delighted to announce it has secured a $15m financing agreement providing it full funding for future growth and accelerated production to drive sales in key markets. Financing will commence in September and be used to; - Fund production for sales of both ArtemiC and MGC Pharmas unique phytocannabinoid medicine products into new key markets including Brazil and UK, to generate revenues for MXC to achieve its target cashflow break-even in H1 2021... - Complete ongoing clinical trials, including completion of Phase II clinical trial of COVID-19 targeted formulation ArtemiC, acceleration of CannEpil Phase IIb clinical trial and continue with Glioblastoma brain cancer research Read the full announcement here: https://stocknessmonster.com/announcements/mxc.asx-6A995300/

16.01.2022 MGC Pharma $MXC has been awarded an Import Licence by the Australian Office of Drug Control and can now directly import Schedule 4 and Schedule 8 MGC products for sale in Australia. Read more here: https://stocknessmonster.com/announcements/mxc.asx-6A985616/

16.01.2022 MGC Pharmaceuticals announces today it has signed a binding term sheet with leading Russian doctor and medical researcher, Dr. Svetlana Kopachevskaja, to establish a joint venture company for medical products in the Russian market. Read the full announcement here: https://stocknessmonster.com/announcements/mxc.asx-6A992677/

16.01.2022 MXC is pleased to announce that In Vivo safety and toxicity pre-clinical study results for ArtemiC on mice in Israel has delivered no adverse results in standard toxicity measures Read more here: https://stocknessmonster.com/announcements/mxc.asx-6A987902/

16.01.2022 FINAL REMINDER: MGC Pharma ShareSoc (UK Individual Shareholders Society) #Webinar TODAY, 5th May 2021 - 5pm (BST) with CEO Roby Zomer and Ron Lipsky (VP, Business Development &IR) presenting. #MXC #MedicalCannabis #BioPharma : https://lnkd.in/dEcxyXG

15.01.2022 https://stockhead.com.au//north-american-fund-backs-mgc-p/

15.01.2022 MGC Pharma updates the market on the ongoing clinical trials for CimetrA, CannEpil, and CogniCann #biopharma #pharmaceuticals #research #development #phytocannabinoid #medicinalcannabis #researchupdate #clinicaltrials https://www.londonstockexchange.com//2021-clinica/14989813

15.01.2022 MGC Pharma has today released an update on the progress of the 100% sale of MGC Nutraceuticals to US Hemp and cannabinoid wellness company, Onassis. - MGC Pharma has recently finalised and provided the 30 June 2020 audited financial statements for MGC Nutraceuticals to Onassis and full settlement of the acquisition is expected to complete over the next five months - Onassis has commenced the process of finalising the offering submissions for the capital raising with the US S...EC. The process from submission to completion is expected to take approximately three months Read the full announcement here: https://stocknessmonster.com/announcemen/mxc.asx-6A1010534/

15.01.2022 MGC Pharmaceuticals is scheduled to release results from its interim analysis of the double-blind Phase II clinical trials on its anti-inflammatory formula ArtemiC on patients with COVID-19 sometime in the next few weeks. What could this mean for investors? https://thegreenfund.com/is-mgc-pharma-sitting-on-a-covid-1

14.01.2022 MGC Pharma $MXC is pleased to announce it has cemented its Australian operations with the signing of a binding term sheet with Cannvalate Pty Ltd to acquire 100% of the operating clinic based assets, data and intellectual property of its wholly owned subsidiary Medicinal Cannabis Clinic Pty Ltd. The acquisition of the MCC Assets will result in a significant decrease in logistics and operational costs for MGC Pharma by increasing the Companys control of the product value chai...n from production to patient as the Company will receive higher profit margins on all three of its production, wholesale and clinic sales. This will also improve MGC Pharmas cashflow earning potential and expedite the Company towards positive cashflow generation and operating profitability. Read more here: https://www.asx.com.au/asxp/20200720/pdf/44knpp61tb3hfl.pdf

13.01.2022 https://stockhead.com.au//mgc-pharma-strengthens-leadersh/

13.01.2022 A recent study conducted at RMIT, Melbourne on the effect of cannabinoids on prostate cancer show a reduction in the size of prostate cancer tumors in animal models read the full report here: https://www.mdpi.com/1422-0067/21/17/6265

12.01.2022 MGC Pharmaceuticals interim results of its novel formula ArtemiC have "demonstrated significant improvement in patients infected with COVID-19." #ArtemiC #MGCPharma #COVID19 https://thegreenfund.com/mgc-pharmas-potential-covid-19-tre

11.01.2022 In a huge leap forward for the sector, the Therapeutic Goods Administration (TGA) has flagged it intends to make cannabidiol (CBD) medicines available without a prescription https://7news.com.au//over-the-counter-medicinal-cannabis-

11.01.2022 MGC Pharma is pleased to announce our Quarterly Activity Report for the three months ended 31st March 2021. See what we've been up to here: #medicinalcannabis #phytocannabinoids #biopharma #pharmaceuticals #quarterlyreport #research #development https://www.londonstockexchange.com//quarterly-re/14951912

11.01.2022 MGC Pharma has signed a distribution agreement with leading UK MC provider Lyphe Group for its cannabinoid medicines MGC Pharma has already received an initial purchase order from LYPHE for 900 units of MXCs affordable Mercury Pharma medicine line of products. This is a direct shipment sale and not consignment stock, indicating the immediate patient demand from the LYPHE network Read the announcement here: https://stocknessmonster.com/announcements/mxc.asx-6A991309/

11.01.2022 https://stockhead.com.au//mgc-pharmas-medical-cannabis-sp/

10.01.2022 "Tests conducted by the company at MyPlant Bio in Israel found a combination of the medical sprays ingredients demonstrated an enhanced effect on human immune function in a manner considered desirable in the treatment of COVID-19. https://stockhead.com.au//mgc-pharmas-medical-spray-could/

10.01.2022 $MXC has today released its quarterly activity report and appendix 4C giving a rundown of commercial and operational highlights from the quarter Read the full announcement here: https://stocknessmonster.com/announcements/mxc.asx-6A989243/

09.01.2022 This week marks #NationalEpilepsyWeek, a campaign focussed on raising awareness around the neurological condition that affects over 600,000 people in the UK. To mark the week, we're proud to announce that we will be making a contribution from sales of our products to childhood epilepsy charities around the world. At @MGCPharma, we strive to support our patients and communities to make their lives better and more comfortable.

08.01.2022 https://thewest.com.au//mgc-pharma-completes-australian-di

07.01.2022 MGC Pharma today announces it has been selected by the World Health Organisation to participate in obtaining mapping and assessment of all ongoing research as part of a COVID-19 taskforce. It has also expanded patient recruitment of its ArtemiC Phase II clinical trial on patients diagnosed with COVID-19 to Mahatma Gandhi Missions Medical College and Hospital in India. This follows a full ethical review where ethics approval has been received. More information can be found here: https://stocknessmonster.com/announcements/mxc.asx-6A984876/

07.01.2022 https://themarketherald.com.au/mgc-pharmaceuticals-asxmxc-/

07.01.2022 MGC Pharma CEO @ZomerRoby will join a @ShareSoc Webinar on 5th May 2021 at 5pm(BST) #biopharma #medicinalcannabis #biotechnology #pharmaceuticals #cannabisindustry Register here: bit.ly/2QpvdkB

06.01.2022 Glow LifeTech (CSE: GLOW), the Canadian-based development and North American distribution partner of MGC Pharma's ArtemiC, has submitted an application to Health Canada to obtain product licenses for ArtemiC as a Natural Health Product. Once Health Canada makes this assessment, they are issued a National Product Number (NPN). ArtemiC is a clinically tested oral spray containing four natural active ingredients: Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The fo...rmulation uses the MyCell delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC was a collaborative development effort between MGC Pharma, Swiss PharmaCan AG, and Glow, and is manufactured by MGC Pharma. #health #technology #innovation #healthcare #development #research #medical #biotechnology #biopharma https://www.londonstockexchange.com//application-/14954412

06.01.2022 https://www.proactiveinvestors.com.au//mgc-pharma-team-dis

06.01.2022 Full results from completed ArtemiC Phase II double-blind, placebo controlled clinical trial are expected in the next 7 days. The results will follow independent technical review and statistical validation of the data which is managed by an external Clinical Research Organization (CRO) under required regulatory conditions addressing FDA (Food and Drug Administration) requirements and following GCP (Good Clinical Practice) guidelines. Read more here: https://stocknessmonster.com/announcemen/mxc.asx-6A1011146/

05.01.2022 We have been made aware that a job description regarding a vacant position at MGC Pharmaceuticals is circulating various jobseeker websites. This is fraudulent and incorrect. Any and all correspondence with a representative from MGC Pharmaceuticals will be via an email address ending with @mgcpharma.com.au. Please disregard and report any advertisements to [email protected].

05.01.2022 https://stockhead.com.au//mgc-pharma-achieves-success-in-/

04.01.2022 One avenue to counteract the damage caused by the pandemic is to identify and treat core factors driving the malignant form of COVID19. These include a prominent disturbance of immunological function ultimately provoking what is known as a Cytokine Storm that results in a severe acute respiratory syndrome with lethal potential (SARS for short), and severe disruption of additional physiological systems potentially leading to a state of shock and death... https://jamanetwork.com//jamainternalm/fullarticle/2767939

04.01.2022 Positive results from the safety study #COVID19 https://thegreenfund.com/animal-study-confirms-safety-of-mg

04.01.2022 To MGC Pharma share holders, hereby Cannaglobal update by Lorne Gertner, -- Dear Friends, Investors, and Advisors of Cannaglobal,...Continue reading

03.01.2022 Australias Therapeutic Goods Administration (TGA) had a busy Julyhas approved a record number of medicinal cannabis applications The TGA figures indicate that 5,564 approvals were issued last month, so nearly 10% of all approvals ever made under SAS Category B occurred in July this year. Julys figures were well up on Junes (4,630) and more than double July last year (2,207). Read more about this here: https://hempgazette.com/n/tga-cannabis-applications-hg1236/

03.01.2022 MGC Pharma strengthens its Board and leadership team with biopharma industry expertise with the appointment of Evan Hayes as an Independent NonExecutive Director and Strategic Advisor, Sabina Suljakovi as Qualified Person and Head of the Quality Assurance in Slovenia and Amir Polak as Chief Technology Officer and Head of Pharmaceutical Production. Read the full announcement here: https://stocknessmonster.com/announcements/mxc.asx-6A993953/

03.01.2022 ArtemiC Phase II Clinical Trial Results on COVID-19 patients confirm 100% of treatment group successfully met primary and secondary endpoints! Read the full results here: https://stocknessmonster.com/announcemen/mxc.asx-6A1012504/

03.01.2022 The director of United in Compassion (UIC) and leading patient advocate Lucy Haslam and Dr Caldicott are launching the Australian Medicinal Cannabis Course Online https://www.healtheuropa.eu/advocacy-group-launches-aust//

02.01.2022 MGC Pharma is delighted to announce that its In-Vitro Study Confirms the effectiveness of ArtemiC on Human Immune Cells to inflammatory stimuli. The final report of results from preclinical in-vitro laboratory testing clearly support the claim that ArtemiC can modify the function of human immune cells in response to inflammatory stimuli Specifically, some elements of the formulation demonstrated an effective response on immune function in a manner considered desirable in th...e treatment of COVID-19 Read the full announcement here: https://stocknessmonster.com/announcements/mxc.asx-6A990379/ $MXC #pharma #healthcare #studyresults #clinicaltrials #research

02.01.2022 MGC Pharma has today announced further results of its ongoing glioblastoma research program in collaboration with the National Institute of Biology (‘NIB’) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia. The pre clinical research program focused on evaluating cannabinoid formulations in the development of a treatment of the most aggressive and therapeutically resistant brain tumour, glioblastoma. These results show that the use of CBD... and CBG double the cytotoxic effect on glioblastoma cells. While CBD inhibits the tumours viability, CBG is more efficient in setting off the cascade of biological processes leading to the specific apoptosis pathways in glioblastoma cells. This is significantly more effective in glioblastoma stem cells GSC’s. These results together with previously announced results (refer ASX release 22 April 2020), significantly progress the Company as they demonstrated efficacy of its new formulations in the treatment of glioblastoma, in particular the stem cells lines is considered to be this critical target in oncology therapy research.

01.01.2022 #ICYMI: MGC Pharma ShareSoc (UK Individual Shareholders Society) #Webinar tomorrow, 5th May 2021 - 5pm (BST) with CEO Roby Zomer and Ron Lipsky (VP, Business Development &IR) presenting. #MXC #MedicalCannabis #BioPharma : https://lnkd.in/dEcxyXG

01.01.2022 Earlier this week, @TheMotleyFool shared their expert insight into MGC Pharma and why we're one to watch this year. If you haven't already done so, click the link below and read their guide. https://www.fool.co.uk//1-high-potential-cannabis-stock-i/